2016 Masterclass in molecular oncology14-15 September 2016 - First module16-17 September 2016 - Second moduleGhent, Belgium

MASTERCLASSPRELIMINARY PROGRAMME

1

OverviewThe past few years have been characterized by a significantimprovement in understanding evolutionary pathways to metastasisand emerging themes are attracting the attention of researchers inthe field of molecular oncology. Metastasis initiation, the biology ofcancer stem cells, tumor cell plasticity and migration, as well as theestablishment of a metastatic niche, are all topics of great interestwhich so far appear to be only partially elucidated. The dissection ofthe metastatic cascade as well as the emerging therapeuticopportunities represent the core of this proposal. The generation anduses of preclinical models to unravel the molecular biology of cancermetastasis will be described and effective tools to conduct atranslational cancer research at interface between basic research andclinical investigation will be provided. To fulfill the above educationalgaps and in line with the current research, EXCEMED designed anddeveloped the successful 2nd Masterclass in Molecular Oncology toextend its curriculum in order to provide HCP’s with knowledge inmolecular oncology and facilitate their ability to design and developsuccessful scientific investigations.

Target audienceMedical oncologists who want to improve their knowledge inmolecular biology platforms for targeted therapy and drug discovery.

Learning objectives: Module IBy attending the Module I of this live educational course participantswill be able to:• Identify the evolutionary pathways to cancer metastasis• Differentiate the analytical methods used to study cancer• Discuss how to personalize treatments based on the molecular

profile of a patient's tumor

Learning objectives: Module IIBy attending the Module II of this live educational course participantswill be able to:• Recognize how to design and implement experiments• Interpret complex data sets• Apply the advances of molecular biology to clinical oncology

2016 Masterclass in molecularoncology

ChairsMartine J. PiccartDepartment of MedicineInstitut Jules Bordet Université Libre de BruxellesBrussels, Belgium

Eric Van CutsemUniversity Hospitals Gasthuisberg / Leuven Leuven, Belgium

Yosef YardenDepartment of Biological RegulationWeizmann Institute of ScienceRehovot, Israel

2

CME ProviderEXCEMED is a non profit foundation dedicated, since the last fourdecades, to the development of high-quality medical educationprogramme all over the world.

EXCEMED adheres to the guidelines and standards of the EuropeanAccreditation Council for Continuing Medical Education (EACCME®)which states that continuing medical education must be balanced,independent, objective, and scientifically rigorous.

Continuing medical educationAn application will be made to the EACCME® for CME accreditation ofthe EXCEMED 2016 Masterclass in molecular oncology to be held on14-15 September 2016 (First module) and 16-17 September 2016(Second module) in Ghent, Belgium.

EXCEMED adheres to the principles of the Good CME Practice group(gCMEp).

3

Faculty

Alberto BardelliIstitute for Cancer Research and Treatment (IRCC) University of TorinoTorino, Italy

Luca GianniDepartment of Medical OncologySan Raffaele Hospital - Scientific InstituteMilan, Italy

Nicola NormannoCell Biology and Biotherapy UnitINT-Fondazione PascaleNaples, Italy

Klaus PantelDepartment of Tumor BiologyUniversity Medical Center Hamburg-EppendorfCenter of Experimental MedicineHamburg, Germany

Martine J. PiccartDepartment of MedicineInstitut Jules Bordet Université Libre de BruxellesBrussels, Belgium

Gregg L. SemenzaInstitute for Cell EngineeringJohns Hopkins University School of MedicineBaltimore, USA

Giulia SiravegnaIstitute for Cancer Research and Treatment (IRCC) University of TorinoTorino, Italy

5

Sabine TejparDigestive Oncology Unit Centre for Human Genetics UZ LeuvenLeuven, Belgium

Livio TrusolinoDepartment of OncologyUniversity of Torino School of MedicineLaboratory of Translational Cancer MedicineCandiolo Cancer Institute - IRCCSCandiolo (Torino), Italy

Samra TurajlicThe Francis Crick Institute and the Royal Marsden HospitalLondon, UK

Eric Van CutsemUniversity Hospitals Gasthuisberg / Leuven Leuven, Belgium

Yosef YardenDepartment of Biological RegulationWeizmann Institute of ScienceRehovot, Israel

6

Programme

Programme

Wednesday, 14 September 2016

13.00 Registrations and light welcome lunch

14.00 Opening keynote lecture: Lessons learned from 15 years of translationalresearch efforts in HER2 positive breast cancer M.J. Piccart (Belgium)

14.45 L1: Molecular characterization technologies(next generation DNA sequencing, gene expressionanalysis, proteomic evaluation, development of bigdata sets)Y. Yarden (Israel)

15.15 L2: HER2-negative breast cancerL. Gianni (Italy)

15.30 Coffee break

15.45 L3: Comprehensive molecular profile of cancer(dissecting tumor heterogeneity through thegenomic sequencing. Lung cancer)N. Normanno (Italy)

16.00 L4: Comprehensive molecular profile of cancer(dissecting tumor heterogeneity through thegenomic sequencing. Colorectal cancer)S. Tejpar (Belgium)

Genomic drivers of cancersSession I

8

MODULE I

Legend: L : Lecture; : Keynote; : Discussion;

16.15 ExercisesPatient resistant across oncological indications• Breast cancer • Lung cancer• Colorectal cancer Key messages from parallel sessions

18.15 End of first day (Module I)

9

MODULE I

Thursday, 15 September 2016

07.30 Early bird session:Signal transduction pathwaysY. Yarden (Israel)

09.00 L5: Basic cancer research: why it is essential for the future of cancer therapy Y. Yarden (Israel)

09.30 L6: Preclinical models for cancer discovery research A. Bardelli (Italy)

10.30 L7: Developing predictive biomarkersS. Tejpar (Belgium)

10.30 Coffee break

10.45 L8: Design of clinical trials in the era of targeted drugsL. Gianni (Italy)

11.15 ExercisesL. Gianni (Italy) - M.J. Piccart (Belgium) S. Tejpar (Belgium) - Y. Yarden (Israel)• Critical analysis of a successful clinical trial • Critical analysis of a non successful clinical trial • Discussion

From signal transduction to cancer precision medicineSession II

10

MODULE I

12.30 Lunch

13.30 L9: Tumor microenvironment biology G.L. Semenza (USA)

14.00 L10: EMT Program and cancer cells plasticitySpeaker to be announced

14.30 L11: Immunity in oncology: from targets to treatmentsSpeaker to be announced

15.00 L12: The blood as an alternative source for actionabletargets in cancer (liquid biopsy)K. Pantel (Germany)

15.30 Coffee break

15.45 Science-medicine tutorials

17.00 Closing keynote lecture: Spatial and temporal dynamics of cancer evolution S. Turajlic (UK)

17.45 End of Module I

20.00 Get together Module I and Module II

Actionable targets on the horizonSession III

11

MODULE I

Friday, 16 September 2016

08.00 Registrations

09.00 Opening keynote lecture: The hallmarks of cancer 2016 Y. Yarden (Israel)

09.45 L1: Angiogenesis and extracellular matrix remodelling G.L. Semenza (USA)

10.15 L2: EMT Program and cancer cells plasticity Speaker to be announced

10.45 Coffee break

11.00 L3: Intratumor heterogeneity and clonal evolution ofcancer S. Turajlic (UK)

11.30 Panel discussion: Do clonal dynamics and heterogeneity constitute anewly understood hallmark of solid tumors?Moderator: Y. Yarden (Israel)

12.30 Lunch

Cancer diagnostic and therapeutics. Actionable targets across tumor typesSession I

12

MODULE II

13.30 Introduction M.J. Piccart (Belgium)

13.45 L4: Monoclonal antibodies E. Van Cutsem (Belgium)

14.15 L5: Tyrosine-kinase inhibitors L. Trusolino (Italy)

14.45 L6: Immune checkpoints inhibitors Speaker to be announced

15.15 Panel discussion: Pros and cons of antibodies kinase inhibitors andimmunotherapy. Can we optimally combine them?Moderator: M.J. Piccart (Belgium)

16.15 Coffee break

16.30 Exercises

• Option A: Adapting clinical trial designs to the challengesof cancer heterogeneity

M.J. Piccart (Belgium)

• Option B: Hypothesis generating experiments, proof ofconcept early phase clinical trials and optimaldesign for genomic clinical trials

Y. Yarden (Israel)

20.30 End of first day (Module II)

The current and emerging armamentarium of medicaloncologistSession II

13

MODULE II

Saturday, 17 September 2016

07.30 Early bird session:Cancer therapeutic resistance Y. Yarden (Israel)

09.00 Introduction Speaker to be announced

09.15 L7: Integrating biomarkers in clinical trialsS. Tejpar (Belgium)

09.45 L8: New molecular models of cancer (PDX, 3D cultures of cancer organoids) L. Trusolino (Italy)

10.15 Coffee break

10.30 L9: New approaches to therapeutic resistance(circulating tumor cells, circulating tumor DNA) G. Siravegna (Italy)

11.00 Panel discussion (Liquid biopsy)Moderator: K. Pantel (Germany)

12.00 Closing keynote lecture: Prioritization of target identification for clinicaltrial entry and routine care M.J. Piccart (Belgium)

12.45 Closing remarks

13.00 End of Module II

Closing Lunch

Predictive and other biomarkers Session III

14

MODULE II

General information

VenueThis live educational course will take place at the:

Ghent Marriott Hotel Korenlei 10, Ghent 9000, Belgium http://www.marriott.com/hotels/travel/gnemc-ghent-marriott-hotel/

LanguageThe official language of this live educational course will be English.

CME ProviderEXCEMED - Excellence in Medical Education

Senior Programme Manager: Alessia AddessiT +39 06 420413 591 - F +39 06 420413 677alesia.addessi@excemed.org

Medical Advisor: Cristina Raimondi cristina.raimondi@libero.it

15

Registration* 1 Module: the registration fee is € 400,00.

2 Modules: the registration fee is € 600,00.

The registration fee includes:• Scientific sessions• Coffee breaks and luncheons• Get together cocktail on 15 September 2016• Educational materials• Certificate of attendance

*The first module attendance is preparatory for the second one.Access to the second module will be allowed only for participantswho attended the 2016 or 2015 first module.

For registration and accommodation please contact:

Meridiano Congress InternationalCongress Manager: David H. SlangenT +39 06 88 595 250 - F +39 06 88 595 234 david.slangen@meridiano.it

16

Visit www.excemed.org

Keep in touch

17

https://twitter.com/EXCEMED_Onco

www.facebook.com/excemed/

www.linkedin.com/company/excemed---excellence-in-medical-education

Take a look at the new website

18

• Six specialty areas, including oncology

• Accessible and accredited e-learning packages

• A world-class repository of CME knowledge andlearning materials

• Monthly updates about our events and resourcesin oncology

• Register with us online and access it all – free

www.excemed.org

Better outcomes for patients start here.With over 40 years in the field, EXCEMED has been delivering CME-accredited programmes longer than any other provider

in Europe, and now offers CME worldwide.

ONCOLOGY NEUROLOGY CARDIOMETABOLIC REPRODUCTIVE MEDICINEIMMUNOLOGY ENDOCRINOLOGY AND METABOLISM SPECIALTY

AREA

LIVE EVENTS LEARNING RESOURCES ONLINE COURSES NEWS

AN EXCLUSIVE FOCUSON CME

Our core mission is to help physicians achieve the best possible outcomes for patients. Our name,EXCEMED, symbolizes a drive for excellence and reflects a passion for delivering the

absolute best in CME. With four decades of achievement behind us and access to the world’spremiere medical experts, better outcomes for patients start here. About EXCEMED.

19

All EXCEMED programmes are organized solely to promote the exchangeand dissemination of scientific and medical information. No forms ofpromotional activities are permitted. There may be presentations discussinginvestigational uses of various products. These views are the responsibility ofthe named speakers, and do not represent an endorsement orrecommendation on the part of EXCEMED. This programme is madepossible thanks to an educational grant received from Merck KGaA,Darmstadt, Germany

EXCEMED - Excellence in Medical EducationHeadquarters14, Rue du Rhône - 1204 Geneva, SwitzerlandRepresentative OfficeSalita di San Nicola da Tolentino 1/b - 00187 Rome, ItalyT +39 06 420413 1 - F +39 06 420413 677

Copyright © EXCEMED, 2016. All rights reserved.

Improving the patient's life through medical educationwww.excemed.org